Luminex Introduces xMAP INTELLIFLEX Flow-Based Multiplex Platform at AACC Clinical Lab Expo

Every year, the global laboratory medicine community comes together as one at the AACC Annual Scientific Meeting & Clinical Lab Expo to collaborate and create system-wide changes that improve patient outcomes and quality of life for all.

Luminex’s xMAP Technology enables the evaluation of up to 500 analytes simultaneously in a single well, known as multiplexing. xMAP Technology uses color-coded microspheres as the substrate on which the solution-phase assays are performed. The microspheres, also known as beads, are read in an xMAP analyzer. Luminex’s xMAP Technology offers the versatility to perform a wide range of protein or nucleic acid based multiplex assays on a single platform.

xMAP INTELLIFLEX is the only compact, flow-based, multiplex platform that combines the proven performance of xMAP Technology with modern features to enhance performance, empower assay development innovation, and simplify your user experience. No other multiplex platform combines low- and high-plex capabilities, quick time to reliable results, and the ability to simultaneously acquire data for two parameters per analyte. With the addition of a second reporter channel, labs can acquire data about two parameters per target protein or nucleic acid, saving time and precious sample. This feature is ideally suited for measuring multiple isotypes or configurations targeting the same antigen.

Other products highlighted by Luminex at AACC 2021 included the VERIGENE II Gastrointestinal Flex Assay which is a sample-to-answer test that detects 24 GI targets, including bacteria, viruses, and parasites, associated with gastroenteritis. The new assay is designed for simple, fast, and flexible detection of infectious GI pathogens. This assay is under development and not currently FDA cleared/CE marked. Also on display at the event was Luminex’s VERIGENE ll Respiratory Flex Assay which is a sample-to-answer test that detects 14 viral pathogens, including SARS-CoV-2, and five bacterial pathogens. This assay is under development and not currently FDA cleared/CE marked.

Related Links:
Luminex Corporation